• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapeutic resistance and combination therapy for cancer: recent developments and future directions.

作者信息

Damodaran Chendil, Cho Je-Yoel, Güngör Cenap

机构信息

Department of Pharmaceutical Science, College of Pharmacy, Texas A&M University, College Station, TX, USA.

Department of Biochemistry, College of Veterinary Medicine, Research Institute for Veterinary Science, and BK21 FOUR Future Veterinary Medicine Leading Education and Research Center, Comparative Medicine Disease Research Center (CDRC), Seoul National University, Seoul, 08826, Republic of Korea.

出版信息

Sci Rep. 2025 Jul 24;15(1):26881. doi: 10.1038/s41598-025-12725-w.

DOI:10.1038/s41598-025-12725-w
PMID:40707669
Abstract
摘要

相似文献

1
Therapeutic resistance and combination therapy for cancer: recent developments and future directions.癌症的治疗耐药性与联合治疗：最新进展与未来方向
Sci Rep. 2025 Jul 24;15(1):26881. doi: 10.1038/s41598-025-12725-w.
2
Emerging nanostructure-based strategies for breast cancer therapy: innovations, challenges, and future directions.基于纳米结构的乳腺癌治疗新策略：创新、挑战与未来方向
Med Oncol. 2025 Apr 30;42(6):188. doi: 10.1007/s12032-025-02743-z.
3
Hybrid Molecules with Purine and Pyrimidine Derivatives for Antitumor Therapy: News, Perspectives, and Future Directions.用于抗肿瘤治疗的含嘌呤和嘧啶衍生物的杂合分子：新进展、前景与未来方向
Molecules. 2025 Jun 23;30(13):2707. doi: 10.3390/molecules30132707.
4
Surface-Modified Carbon Dots for Cancer Therapy: Integrating Diagnostic and Therapeutic Applications.用于癌症治疗的表面改性碳点：整合诊断与治疗应用
Int J Nanomedicine. 2025 Jun 16;20:7715-7741. doi: 10.2147/IJN.S508181. eCollection 2025.
5
Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC).三阴性乳腺癌（TNBC）联合免疫疗法与其他疗法及基于纳米颗粒的疗法的最新进展
Cancers (Basel). 2024 May 25;16(11):2012. doi: 10.3390/cancers16112012.
6
Therapeutic Indications of Pembrolizumab in Eight Common Cancers: Current Evidence and Future Directions.帕博利珠单抗在八种常见癌症中的治疗适应症：当前证据与未来方向
Cancer Rep (Hoboken). 2025 Jul;8(7):e70234. doi: 10.1002/cnr2.70234.
7
Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors.使胃癌对免疫检查点抑制剂敏感的当前进展与未来方向
Cancer Med. 2025 Jul;14(14):e71065. doi: 10.1002/cam4.71065.
8
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.破解表皮生长因子受体密码：癌症生物学、耐药机制及未来治疗前沿
Pharmacol Rev. 2025 Jun 25;77(5):100076. doi: 10.1016/j.pharmr.2025.100076.
9
Emerging Research and Future Directions on Doxorubicin: A Snapshot.阿霉素的新兴研究与未来方向：概述
Asian Pac J Cancer Prev. 2025 Jan 1;26(1):5-15. doi: 10.31557/APJCP.2025.26.1.5.
10
Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies.肺癌中的生物标志物与免疫评分：免疫治疗及联合治疗策略的预测性见解
Biol Proced Online. 2025 Jul 10;27(1):25. doi: 10.1186/s12575-025-00287-0.

本文引用的文献

1
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.三阴性乳腺癌对紫杉醇的反应模拟了干扰素反应，揭示了细胞周期相关的耐药机制。
Sci Rep. 2025 Feb 4;15(1):4294. doi: 10.1038/s41598-024-82218-9.
2
Targeting mitochondrial RNAs enhances the efficacy of the DNA-demethylating agents.靶向线粒体RNA可提高DNA去甲基化剂的疗效。
Sci Rep. 2024 Dec 28;14(1):30767. doi: 10.1038/s41598-024-80834-z.
3
Trop2-targeted therapies in solid tumors: advances and future directions.实体瘤中 Trop2 靶向治疗：进展与未来方向。
Theranostics. 2024 Jun 11;14(9):3674-3692. doi: 10.7150/thno.98178. eCollection 2024.
4
Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers.质子或 X 射线照射联合抗 PD-L1 免疫治疗两种小鼠口腔癌。
Sci Rep. 2024 May 21;14(1):11569. doi: 10.1038/s41598-024-62272-z.
5
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.一种新型的抗 LAG-3/TIGIT 双特异性抗体在作为单药或与 PD-1 抗体联合治疗的小鼠模型中显示出强大的抗肿瘤疗效。
Sci Rep. 2024 May 9;14(1):10661. doi: 10.1038/s41598-024-61477-6.
6
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.靶向葡萄糖神经酰胺合酶在奥希替尼耐药 NSCLC 细胞模型中诱导抗增殖和促凋亡作用。
Sci Rep. 2024 Mar 18;14(1):6491. doi: 10.1038/s41598-024-57028-8.
7
Aryl hydrocarbon receptor suppresses STING-mediated type I IFN expression in triple-negative breast cancer.芳香烃受体抑制三阴性乳腺癌中 STING 介导的 I 型 IFN 表达。
Sci Rep. 2024 Mar 8;14(1):5731. doi: 10.1038/s41598-024-54732-3.
8
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2 ovarian cancer cells.靶向抑制 ATR/CHK1 通路可克服奥拉帕利耐药性，并调节 BRCA2 卵巢癌细胞中 DNA 损伤反应蛋白的表达。
Sci Rep. 2023 Dec 19;13(1):22659. doi: 10.1038/s41598-023-50151-y.
9
Overcoming PARP inhibitor resistance in ovarian cancer.克服卵巢癌中 PARP 抑制剂的耐药性。
Int J Gynecol Cancer. 2023 Mar 6;33(3):364-376. doi: 10.1136/ijgc-2022-003698.
10
Tamoxifen evolution.他莫昔芬的演变
Br J Cancer. 2023 Feb;128(3):421-425. doi: 10.1038/s41416-023-02158-5. Epub 2023 Feb 10.